OncoMatch/Clinical Trials/NCT07330050
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Is NCT07330050 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Whole Agonist-Stimulated T (WAST) cells and Docetaxel for nsclc (non-small cell lung cancer).
Treatment: Whole Agonist-Stimulated T (WAST) cells · Docetaxel — This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-pd-1 therapy — first-line
Cannot have received: adoptive cell therapy
Lab requirements
Blood counts
ANC >1.5×10⁹/L; ALC ≥0.3×10⁹/L; Platelets ≥100×10⁹/L; Hemoglobin ≥100g/L
Kidney function
Serum creatinine ≤1.5x ULN, or creatinine clearance rate ≥60 mL/min
Liver function
AST ≤2.5x ULN (≤5 ULN if due to tumor infiltration); ALT ≤2.5x ULN (≤5 ULN if due to tumor infiltration); Total serum bilirubin ≤1.5x ULN (≤3 ULN if due to tumor infiltration)
Cardiac function
LVEF ≤50% (by ECHO); NYHA class III or IV congestive heart failure; Uncontrolled hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) or pulmonary hypertension despite standard treatment; Myocardial infarction or cardiac surgery within 12 months prior to cell infusion; Clinically significant valvular heart disease
Adequate organ function at screening, meeting the following criteria: AST ≤2.5x ULN (≤5 ULN if due to tumor infiltration); ALT ≤2.5x ULN (≤5 ULN if due to tumor infiltration); Total serum bilirubin ≤1.5x ULN (≤3 ULN if due to tumor infiltration); Serum creatinine ≤1.5x ULN, or creatinine clearance rate ≥60 mL/min; Minimum lung reserve level, defined as ≤Grade 1 dyspnea and oxygen saturation >91% without supplemental oxygen; INR ≤1.5x ULN, and APTT ≤1.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07330050 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adoptive cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages